EyePoint Pharmaceuticals, Inc. granted non-statutory stock options to new employees as inducement awards. The options allow the purchase of up to 18,000 shares of common stock at $11.09 per share. The options vest over four years, with 25% vesting on the first anniversary. EyePoint is focused on developing innovative therapeutics for retinal diseases, with lead product candidate DURAVYU™ in Phase 3 trials for wet age-related macular degeneration (wet AMD) and positive Phase 2 results for diabetic macular edema (DME). The company aims to improve patient lives and create long-term value with its innovative treatments.

Read more at GlobeNewswire: EyePoint Reports Inducement Grants Under NASDAQ Listing